United Kingdom

People: Constellation Pharmaceuticals Inc (CNST.OQ)

CNST.OQ on NASDAQ Stock Exchange Global Select Market

16 Aug 2019
Change (% chg)

$0.90 (+12.78%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Senderowicz, Adrian 

Dr. Adrian Senderowicz, M.D. serves as Senior Vice President and Chief Medical Officer of the company since July 2017, prior to which he provided consulting services to us from May 2017 until the commencement of his employment with us. Prior to joining us, Dr. Senderowicz served as chief medical officer at Cerulean Pharma, Inc., an oncology-focused biotechnology company now known as Daré Bioscience, Inc., from September 2015 to June 2017, where he helped secure Fast Track designation for the company’s lead clinical development program in two indications. Previously, Dr. Senderowicz was chief medical officer and senior vice president, clinical development and regulatory affairs at Ignyta, Inc., a biotechnology company, from August 2014 to April 2015. Prior to that he was vice president, global oncology regulatory head at Sanofi S.A., a global pharmaceutical company, from July 2013 to August 2014 and served as chief medical officer at Tokai Pharmaceuticals, Inc., a biopharmaceutical company now known as Novus Therapeutics, Inc., from August 2012 to March 2013. Dr. Senderowicz was a medical director and senior medical director at AstraZeneca PLC, a global biopharmaceutical company, from 2008 to 2012. He began his career as an investigator at the National Cancer Institute before joining the Center for Drug Evaluation and Research at the FDA. Since September 2015, Dr. Senderowicz has served on the board of directors of Puma Biotechnology, a public biotechnology company. Dr. Senderowicz is a board-certified medical oncologist. Dr. Senderowicz completed his Internal Medicine residency training at the Icahn School of Medicine at Mount Sinai and a Clinical Oncology Fellowship at the National Cancer Institute. He holds an M.D. degree from the School of Medicine at the Universidad de Buenos Aires in Argentina.

Basic Compensation

Total Annual Compensation, USD 311,081
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 1,208,150
Fiscal Year Total, USD 1,519,230

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --